RT Journal Article
T1 The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination
A1 López Muguruza, Eneritz
A1 Villar Gómez, Natalia
A1 Matías-Guiu Guia, Jordi A.
A1 Selma Calvo, Belen
A1 Moreno Jiménez, Lidia
A1 Sancho Bielsa, Francisco
A1 Lopez Carbonero, Juan
A1 Benito Martín, María Soledad
A1 García Flores, Silvia
A1 Bonel García, Natalia
A1 Kamal, Ola Mohamed Fathy
A1 Ojeda Hernández, Doddy Denise
A1 Matías-Guiu Guía, Jorge
A1 Gómez Pinedo, Ulises
AB Multiple sclerosis (MS) is a chronic degenerative autoimmune disease of the central nervous system that causes inflammation, demyelinating lesions, and axonal damage and is associated with a high rate of early-onset disability. Disease-modifying therapies are used to mitigate the inflammatory process in MS but do not promote regeneration or remyelination; cell therapy may play an important role in these processes, modulating inflammation and promoting the repopulation of oligodendrocytes, which are responsible for myelin repair. The development of genetic engineering has led to the emergence of stable, biocompatible biomaterials that may promote a favorable environment for exogenous cells. This review summarizes the available evidence about the effects of transplantation of different types of stem cells reported in studies with several animal models of MS and clinical trials in human patients. We also address the advantages of combining cell therapy with biomaterials.
PB MPDI
SN 2075-1729
YR 2022
FD 2022-03-24
LK https://hdl.handle.net/20.500.14352/71734
UL https://hdl.handle.net/20.500.14352/71734
LA eng
NO López Muguruza, E., Villar Gómez, N., Matías-Guiu Guia, J. A. et al. «The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination». Life, vol. 12, n.o 4, marzo de 2022, p. 474. DOI.org (Crossref), https://doi.org/10.3390/life12040474.
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 10 abr 2025